NEW YORK (GenomeWeb News) – Foundation Medicine's supply, service, and support agreement with Illumina inked in July is for five years and approximately $6.1 million, the Cambridge, Mass.-based firm said in an amended Form S-1 filed this week. The company originally disclosed the deal with Illumina in its Form S-1 filed in July in preparation of its initial public offering, but did not reveal the terms. Foundation plans to offer up to $86.3 million in its IPO.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Science this week: caution urged in use of gene drives, and more.

NIH's Sally Rockey examines the tapped and untapped potential of the NIH peer reviewer pool.

PLOS Biology has asked researchers how they envision the future of genetics and genomics.

Representative Lamar Smith brings back a provision to require the National Science Foundation to certify that each study it funds is "in the national interest."